Don't take this as gospel but I'm reasonably sure that share based payment charges don't involve the actual issue of any shares. If they did, we'd have seen an "Additional Listing" RNS and, though we had one, in november it was for a fairly small amount. i might have missed one though
Basically i think it's just recognising possible future options as a liability on the books.
The only reason I asked was whether it may have had anything to do with the odd trades, not that anyone can really say for sure. Actually amounts to a lot of shares when you see the total figure, so good to know there aren't huge amount more options hanging over future progress.
By the time of the AGM statement, we'll not have seen a further half year of performance, but we have of course passed Q1. I asked Ian Ford if quarterly updates would be appropriate as the company moves to a cash generation phase, and he did say it was something they would consider. I guess this time may be too early.
Page 37 or thereabouts. Ford on 49k, Buck on 35k. Caveated with the fact that Buck was just Chair then and is now Exec Chair so might have taken a pay rise ( doubt he has though ).
To be honest I don't know enough about the mechanics of "share based payments" work when directors leave a company and how it's shown in the accounts. It doesn't effect cash-flow so I'm just going to ignore it
Note your comment on 'tother channel. Where did you find the ongoing salaries, as opposed to what was a mixed up year with SiS involved? What do you make of "Share based payments, equity settled? Went up a lot, would that explain the former CEO now not holding options?
The last paragraph confirms again that demand and production to meet demand is growing to a point where revenues will now start increasing for DSM and Provexis. And an increase in revenues will reflect an increase in company value and increase in share price year on year as demand continues to increase. .IMHO.
"DSM has invested substantial resource into establishing a commercial scale supply chain for powder manufacturing and cost of goods has been high in this start-up phase, on a low volume base, which is typical for a new ingredient launch. DSM’s manufacturing and technical teams have been highly focused on reducing Fruitflow® production costs and as manufacturing volume increases unit costs will decrease, enabling more positive margins and thus profit distributions to Provexis."
"The initial powder manufacturing setup phase for Fruitflow® has now been concluded, and a reduction in Fruitflow® powder production costs was realised towards the close of the quarter ended 30 June 2014"
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.